Drug susceptibility testing of nontuberculous mycobacteria

Demonstration of Plasmid-Mediated Drug Resistance in Mycobacterium abscessus

(2014) C. K. Matsumoto et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: the evidence

(2013) Jakko van Ingen et al.   Expert Review of Anti-Infective Therapy

Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance

(2013) Jakko van Ingen et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections

(2013) C. Magis-Escurra et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Adherence and biofilm formation ofMycobacterium avium,Mycobacterium intracellulareandMycobacterium abscessusto household plumbing materials

(2013) S.N. Mullis et al.   JOURNAL OF APPLIED MICROBIOLOGY

In Vitro Activity of Amikacin against Isolates of Mycobacterium avium Complex with Proposed MIC Breakpoints and Finding of a 16S rRNA Gene Mutation in Treated Isolates

(2013) B. A. Brown-Elliott et al.   JOURNAL OF CLINICAL MICROBIOLOGY

In Vivo Evaluation of Antibiotic Activity Against Mycobacterium abscessus

(2013) Isabelle Lerat et al.   JOURNAL OF INFECTIOUS DISEASES

The Pharmacokinetics and Pharmacodynamics of PulmonaryMycobacterium aviumComplex Disease Treatment

(2012) Jakko van Ingen et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Therapeutic Drug Monitoring in the Treatment ofMycobacterium aviumComplex Lung Disease

(2012) Won-Jung Koh et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

ESX-1-mediated translocation to the cytosol controls virulence of mycobacteria

(2012) Diane Houben et al.   CELLULAR MICROBIOLOGY

Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria

(2012) Jakko van Ingen et al.   DRUG RESISTANCE UPDATES

Mycobacterium iranicum sp. nov., a rapidly growing scotochromogenic species isolated from clinical specimens on three different continents

(2012) H. Shojaei et al.   INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY

Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?

(2011) J. van Ingen et al.   CLINICAL INFECTIOUS DISEASES

Clinical and Microbiologic Outcomes in Patients Receiving Treatment for Mycobacterium abscessus Pulmonary Disease

(2011) Julie Jarand et al.   CLINICAL INFECTIOUS DISEASES

The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach

(2011) J.W. Mouton et al.   CLINICAL MICROBIOLOGY AND INFECTION

Are phylogenetic position, virulence, drug susceptibility and in vivo response to treatment in mycobacteria interrelated?

(2011) Jakko van Ingen et al.   INFECTION GENETICS AND EVOLUTION

Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease

(2011) Jakko van Ingen et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Automated quantitative drug susceptibility testing of non-tuberculous mycobacteria using MGIT 960/EpiCenter TB eXiST

(2011) Katja Lucke et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Clinical Significance of Differentiation ofMycobacterium massiliensefromMycobacterium abscessus

(2010) Won-Jung Koh et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Ethambutol Optimal Clinical Dose and Susceptibility Breakpoint Identification by Use of a Novel Pharmacokinetic-Pharmacodynamic Model of Disseminated Intracellular Mycobacterium avium

(2010) D. Deshpande et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Assessment of Clarithromycin Susceptibility in Strains Belonging to theMycobacterium abscessusGroup byerm(41) andrrlSequencing

(2010) Sylvaine Bastian et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Application of a feasible method for determination of biofilm antimicrobial susceptibility in staphylococci

(2010) ANA LÚCIA SOUZA ANTUNES et al.   APMIS

Antibiotic Treatment ofMycobacterium abscessusLung Disease

(2009) Kyeongman Jeon et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

A Novel Gene, erm(41), Confers Inducible Macrolide Resistance to Clinical Isolates of Mycobacterium abscessus but Is Absent from Mycobacterium chelonae

(2009) K. A. Nash et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The Netherlands

(2009) Jakko van Ingen et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Comparison of three methods for susceptibility testing of Mycobacterium avium subsp. paratuberculosis to 11 antimicrobial drugs

(2009) M. Y. Krishnan et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Surrounded by mycobacteria: nontuberculous mycobacteria in the human environment

(2009) J.O. Falkinham et al.   JOURNAL OF APPLIED MICROBIOLOGY

Insights from the complete genome sequence of Mycobacterium marinum on the evolution of Mycobacterium tuberculosis

(2008) T. P. Stinear et al.   GENOME RESEARCH

Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy

(2008) P A Jenkins et al.   THORAX

The early bactericidal activity of anti-tuberculosis drugs: a literature review

(2008) P.R. Donald et al.   TUBERCULOSIS